07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Inhibitor of DNA binding 1 (ID1)

Cancer INDICATION: Cancer Studies in patients and mice suggest inhibiting ID1 could help treat cancer. In peripheral blood monocytes from patients with metastatic breast cancer or metastatic melanoma, ID1 levels were higher than in monocytes...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

AngioGenex preclinical data

In a mouse model of breast cancer, twice-daily AGX-51 significantly blocked tumor growth at a dose <7 mg/kg when given in combination with a taxane and completely blocked tumor-associated angiogenesis when given alone at a...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Clinical News

AngioGenex preclinical data

Data from a xenograft mouse model of cancer showed that AGX-51 produced significant tumor inhibition compared with saline control at day 10 (p<0.01). Additionally, mice treated with AGX-51 plus Taxol paclitaxel from Bristol-Myers Squibb Co....
08:00 , Feb 9, 2009 |  BC Week In Review  |  Clinical News

AngioGenex preclinical data

Data from a xenograft mouse model of cancer showed that 30 mg/kg AGX-8 produced 41% tumor inhibition compared to saline control (p<0.01). AGX-8 is an inhibitor of DNA binding 1 (Id1) inhibitor. Data were presented...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

AngioGenex management update

AngioGenex Inc. (OTCBB:AGGX), New York, N.Y.   Business: Cancer   Promoted: William Garland to CEO while remaining COO; he replaces Richard Salvador, who will remain president and a director  ...
07:00 , Apr 10, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Metastatic breast cancer Id1 Studies in mice suggest that inhibiting Id1 could help treat metastatic breast and other cancers. Id1 is...
08:00 , Feb 28, 2008 |  BC Innovations  |  Tools & Techniques

PCAOs: Uncommon Antisense

Transcription factors and other molecules involved in interactions inside cell nuclei are important targets for treating many diseases, but a number of characteristics have made them difficult drug targets. A research team from Memorial Sloan-Kettering...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Company News

AngioGenex board of directors update

AngioGenex Inc. (OTCBB:AGGX), New York, N.Y.   Business: Cancer   Appointed: Acting President and CEO Richard Salvador as chairman; he replaces Michael Strage who will remain VP of business development and a director; and William...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Clinical News

AngioGenex preclinical data

In mouse models of breast and lung cancer, IV administration of Id1-PCAOs significantly decreased Id1 levels in the epithelium and increased hemorrhage in both types of tumors. The compounds are peptide-conjugated antisense oligonucleotides (PCAOs), including...
07:00 , Apr 22, 2004 |  BC Extra  |  Company News

AngioGenex, BioCheck cancer diagnostic deal

AngioGenex (New York, N.Y.) granted BioCheck (Foster City, Calif.) exclusive rights to develop and market cancer diagnostic and prognostic products based on AngioGenex's Id-gene technology. The companies said the presence of Id proteins is associated...